

Denis L Jardim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9413705/publications.pdf>

Version: 2024-02-01

22
papers

349
citations

1162367

8
h-index

839053

18
g-index

24
all docs

24
docs citations

24
times ranked

656
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv253. | 3.0 | 139 |
| 2 | Predictive Value of Phase I Trials for Safety in Later Trials and Final Approved Dose: Analysis of 61 Approved Cancer Drugs. <i>Clinical Cancer Research</i> , 2014, 20, 281-288. | 3.2 | 46 |
| 3 | Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities. <i>Cancer</i> , 2019, 125, 1185-1199. | 2.0 | 36 |
| 4 | Impact of the COVID-19 Pandemic on Oncology Clinical Research in Latin America (LACOG 0420). <i>JCO Global Oncology</i> , 2021, 7, 649-658. | 0.8 | 19 |
| 5 | Cyclin Pathway Genomic Alterations Across 190,247 Solid Tumors: Leveraging Large-Scale Data to Inform Therapeutic Directions. <i>Oncologist</i> , 2021, 26, e78-e89. | 1.9 | 18 |
| 6 | Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds. <i>Oncolimmunology</i> , 2020, 9, 1710052. | 2.1 | 17 |
| 7 | Spectrum and Clinical Activity of PD-1/PD-L1 Inhibitors: Regulatory Approval and Under Development. <i>Current Oncology Reports</i> , 2020, 22, 70. | 1.8 | 11 |
| 8 | Consensus on the Treatment and Follow-Up for Metastatic Castration-Resistant Prostate Cancer: A Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCDC). <i>JCO Global Oncology</i> , 2021, 7, 559-571. | 0.8 | 10 |
| 9 | Identification of the TP53 p.R337H Variant in Tumor Genomic Profiling Should Prompt Consideration of Germline Testing for Li-Fraumeni Syndrome. <i>JCO Global Oncology</i> , 2021, 7, 1141-1150. | 0.8 | 7 |
| 10 | Oncology Clinical Trials During the COVID-19 Pandemic. <i>Oncology</i> , 2020, 34, 265-269. | 0.4 | 7 |
| 11 | Expression of Sara2 Human Gene in Erythroid Progenitors. <i>BMB Reports</i> , 2005, 38, 328-333. | 1.1 | 6 |
| 12 | Impact of the biomarker enrichment strategy in drug development. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 611-618. | 1.5 | 5 |
| 13 | Landscape of Cyclin Pathway Genomic Alterations Across 5,356 Prostate Cancers: Implications for Targeted Therapeutics. <i>Oncologist</i> , 2021, 26, e715-e718. | 1.9 | 5 |
| 14 | SARS-CoV-2 testing for asymptomatic adult cancer patients before initiating systemic treatments: a systematic review. <i>Ecancermedicalscience</i> , 2020, 14, 1100. | 0.6 | 5 |
| 15 | Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective. <i>Journal of Medical Economics</i> , 2021, 24, 291-298. | 1.0 | 4 |
| 16 | Renal cell cancer treatment: an expert panel recommendation from the Latin American cooperative group-genitourinary and the Latin American renal cancer group: focus on surgery. <i>Therapeutic Advances in Urology</i> , 2019, 11, 175628721987232. | 0.9 | 3 |
| 17 | Advanced renal cell carcinoma (RCC) management: an expert panel recommendation from the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG). <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1829-1845. | 1.2 | 3 |
| 18 | Consensus on the Treatment and Follow-Up for the Nonmetastatic Castration-Resistant Prostate Cancer: A Report From the First Prostate Cancer Consensus Conference for Developing Countries. <i>JCO Global Oncology</i> , 2021, 7, 545-549. | 0.8 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Meta-analysis of randomized clinical trials (RCT) for the adjuvant treatment of renal cell carcinoma (RCC) with vascular endothelial growth factor receptor tyrosine-kinase inhibitors (VEGFR TKIs).. Journal of Clinical Oncology, 2019, 37, 4579-4579. | 0.8 | 1 |
| 20 | Response. Journal of the National Cancer Institute, 2016, 108, djw001. | 3.0 | 0 |
| 21 | Cardiovascular toxicity incidence following immune checkpoint inhibitors in randomized clinical trials: A systematic review and meta-analysis.. Journal of Clinical Oncology, 2021, 39, 2636-2636. | 0.8 | 0 |
| 22 | Association between tumor mutational burden (TMB) and mutational profile and its effect on overall survival: A post hoc analysis of patients with TMB-high and TMB-low metastatic cancer treated with immune checkpoint inhibitors (ICI).. Journal of Clinical Oncology, 2022, 40, 2632-2632. | 0.8 | 0 |